Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus

Author(s): Shi P, Liu W, Zhou ZT, He QB, Jiang WW

Abstract

Background: Oral lichen planus (OLP) is a potentially malignant disorder associated with an increased risk for oral cancer. The purpose of this study was to determine protein expression of podoplanin and ATP-binding cassette, G2 subfamily (ABCG2) in patients with OLP and evaluate their use as biomarkers for OLP malignant transformation risk.

Methods: Podoplanin and ABCG2 expressions were determined in samples from 110 patients with untransformed OLP and 9 patients with malignant transformed OLP (mean follow-up of 5.1 years). We compared podoplanin expression, ABCG2 expression, and clinicopathologic parameters between the two groups.

Results: Podoplanin expression was observed in 48 of 110 (43.6%) cases of untransformed OLP and in 8 of 9 (88.9%) cases of transformed OLP. ABCG2 expression was found in 23 of 110 (20.9%) cases of untransformed OLP and in 6 of 9 (66.7%) cases of transformed OLP. Multivariate regression analysis revealed that podoplanin or ABCG2 expression was associated with 17.13-fold [95% confidence interval (95% CI), 1.71-171.22; P = 0.016] or 6.04-fold (95% CI, 1.20-30.36; P = 0.029) increased risk of malignant transformation, respectively. The risk of OLP malignant transformation was considerably higher with coexpression of podoplanin and ABCG2 than without coexpression of podoplanin and ABCG2 (odds ratio, 25.24; 95% CI, 4.48-142.27; P < 0.001).

Conclusions: The expressions of podoplanin and ABCG2 in OLP were significantly associated with malignant transformation risk.

Impact: Our data suggested that podoplanin and ABCG2 may be used as biomarkers for risk assessment of oral malignant transformation in patients with OLP.

Similar Articles

Overexpression of podoplanin in oral cancer and its association with poor clinical outcome

Author(s): Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, et al.

Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas

Author(s): Rodrigo JP, García-Carracedo D, González MV, Mancebo G, Fresno MF, et al.

The role of podoplanin in tumor progression and metastasis

Author(s): Raica M, Cimpean AM, Ribatti D

Genetics/epigenetics of oral premalignancy: current status and future research

Author(s): Lingen MW, Pinto A, Mendes RA, Franchini R, Czerninski R, et al.

Overexpression of podoplanin in oral cancer and its association with poor clinical outcome

Author(s): Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, et al.

The significance of podoplanin expression in human inflamed gingiva

Author(s): Miyazaki Y, Okamoto E, González-Alva P, Hayashi J, Ishige T, et al.

Podoplanin expression in odontomas: clinicopathological study and immunohistochemical analysis of 86 cases

Author(s): González-Alva P, Inoue H, Miyazaki Y, Tsuchiya H, Noguchi Y, et al.

Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy

Author(s): Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, et al.

Podoplanin expression in oral leukoplakia: tumorigenic role

Author(s): De Vicente JC, Rodrigo JP, Rodriguez-Santamarta T, Lequerica-Fernández P, Allonca E, et al.

Overexpression of podoplanin in oral cancer and its association with poor clinical outcome

Author(s): Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, et al.

The potential role of podoplanin in tumour invasion

Author(s): Wicki A, Christofori G

The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis

Author(s): Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, et al.

Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition

Author(s): Martín-Villar E, Megías D, Castel S, Yurrita MM, Vilaró S, et al.

Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431

Author(s): Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, et al.

The potential role of podoplanin in tumour invasion

Author(s): Wicki A, Christofori G